What type of study is this?

This is a Phase 2 study (also classified as: Human Clinical Trial).

September 5, 2025JAMA Internal MedicineOpen Access

Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial finds azelastine nasal spray reduces SARS-CoV-2 infections in healthy adults, suggesting a potential prophylactic treatment option.

Azelastine nasal spray significantly reduced the incidence of SARS-CoV-2 infections compared to placebo.
Only 2.2% of participants using azelastine were infected, versus 6.7% in the placebo group, demonstrating substantial efficacy.
This phase 2, double-blind trial included 450 healthy adults, enrolled to evaluate the efficacy of azelastine as a preventive measure.
These findings highlight the potential of azelastine for COVID-19 prophylaxis, but larger trials are needed to confirm results.

Lehr et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 5, 2025JAMA Internal MedicineOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial finds azelastine nasal spray reduces SARS-CoV-2 infections in healthy adults, suggesting a potential prophylactic treatment option.

Azelastine nasal spray significantly reduced the incidence of SARS-CoV-2 infections compared to placebo.
Only 2.2% of participants using azelastine were infected, versus 6.7% in the placebo group, demonstrating substantial efficacy.
This phase 2, double-blind trial included 450 healthy adults, enrolled to evaluate the efficacy of azelastine as a preventive measure.
These findings highlight the potential of azelastine for COVID-19 prophylaxis, but larger trials are needed to confirm results.

Lehr et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark